Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Shares Bought by Victory Capital Management Inc.

Victory Capital Management Inc. grew its holdings in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 65.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 96,273 shares of the company’s stock after purchasing an additional 37,946 shares during the period. Victory Capital Management Inc.’s holdings in Maravai LifeSciences were worth $525,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. VELA Investment Management LLC increased its position in Maravai LifeSciences by 54.5% during the 4th quarter. VELA Investment Management LLC now owns 148,112 shares of the company’s stock worth $807,000 after purchasing an additional 52,246 shares during the period. Y Intercept Hong Kong Ltd boosted its stake in shares of Maravai LifeSciences by 155.9% during the 4th quarter. Y Intercept Hong Kong Ltd now owns 32,359 shares of the company’s stock worth $176,000 after acquiring an additional 19,713 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of Maravai LifeSciences by 9.9% during the 4th quarter. Rhumbline Advisers now owns 185,221 shares of the company’s stock worth $1,009,000 after acquiring an additional 16,712 shares in the last quarter. Empowered Funds LLC purchased a new stake in shares of Maravai LifeSciences during the 4th quarter worth approximately $155,000. Finally, Bleakley Financial Group LLC boosted its stake in shares of Maravai LifeSciences by 30.1% during the 4th quarter. Bleakley Financial Group LLC now owns 41,691 shares of the company’s stock worth $227,000 after acquiring an additional 9,657 shares in the last quarter. Institutional investors and hedge funds own 50.25% of the company’s stock.

Insiders Place Their Bets

In other news, General Counsel Kurt Oreshack sold 25,000 shares of the firm’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $5.03, for a total transaction of $125,750.00. Following the sale, the general counsel now owns 167,618 shares in the company, valued at $843,118.54. This trade represents a 12.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.63% of the company’s stock.

Maravai LifeSciences Price Performance

MRVI stock opened at $2.27 on Friday. Maravai LifeSciences Holdings, Inc. has a 1 year low of $2.07 and a 1 year high of $11.56. The company has a debt-to-equity ratio of 0.89, a quick ratio of 9.94 and a current ratio of 10.74. The stock’s 50 day moving average price is $3.96 and its 200 day moving average price is $5.83. The firm has a market cap of $573.24 million, a P/E ratio of -1.38 and a beta of -0.08.

Analyst Ratings Changes

Several brokerages have recently commented on MRVI. Bank of America decreased their price target on Maravai LifeSciences from $9.00 to $8.00 and set a “buy” rating on the stock in a research note on Monday, March 3rd. UBS Group decreased their price target on Maravai LifeSciences from $8.00 to $2.50 and set a “neutral” rating on the stock in a research note on Friday. The Goldman Sachs Group lowered Maravai LifeSciences from a “neutral” rating to a “sell” rating and decreased their price target for the stock from $7.00 to $4.25 in a research note on Thursday, December 5th. Robert W. Baird lowered Maravai LifeSciences from an “outperform” rating to a “neutral” rating and decreased their price target for the stock from $9.00 to $3.00 in a research note on Wednesday, February 26th. Finally, Guggenheim initiated coverage on Maravai LifeSciences in a research note on Thursday, December 19th. They issued a “neutral” rating on the stock. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $8.22.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.